InSilicoTrials Joins Microsoft for Startups Pegasus Program to Accelerate Digital Transformation in Healthcare
The Microsoft for Startups Pegasus Program connects growth-stage startups with Microsoft's global sales channels and enterprise customer network. The program is designed for startups with demonstrated product-market fit and the ability to scale in sectors such as AI, healthcare, cybersecurity, and retail.
As part of the Microsoft for Startups Pegasus Program, InSilicoTrials will use Microsoft Azure's cloud infrastructure and AI capabilities to further develop its digital simulation platform. This platform supports pharmaceutical and biotech companies, as well as researchers, in accelerating R&D, optimizing clinical trial designs, and reducing dependence on traditional clinical studies. InSilicoTrials' technology includes digital twin and virtual patient models, AI-based simulations, and privacy-preserving synthetic patient populations—tools designed to improve the efficiency and effectiveness of drug development.
'InSilicoTrials is focused on expanding access to simulation and AI tools that help life sciences organizations de-risk faster development of safer, more effective treatments,' said Luca Emili, CEO at InSilicoTrials. 'Joining the Microsoft for Startups Pegasus Program allows us to scale our reach, enhance our integration with Microsoft Azure, and bring the benefits of in silico trials to more customers worldwide.'
Participation in the Microsoft for Startups Pegasus Program will also enable InSilicoTrials to offer its solutions via the Azure Marketplace, making it easier for enterprise customers to access its cloud-based platform. The company will also engage in co-sell opportunities and joint go-to-market efforts alongside Microsoft's technical and sales teams.
'We are pleased to welcome InSilicoTrials into the Microsoft for Startups Pegasus Program. We look forward to supporting their efforts to bring advanced digital simulation and AI technologies to life sciences organizations that are transforming healthcare, accelerating innovation and accelerating drug development,' commented Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups.
For more information about InSilicoTrials and its digital healthcare solutions, visit https://insilicotrials.com/.
About InSilicoTrials
InSilicoTrials is a digital health startup founded by experts in life sciences, cybersecurity, and digital innovation. Its cloud-based platform leverages AI and simulation to predict drug safety and efficacy, accelerate R&D, and streamline clinical trial processes for pharmaceutical, biotech, and research organizations. With a global network of more than 70 scientific partners and hundreds of integrated models, InSilicoTrials is helping organizations modernize and improve drug development workflows.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 days ago
- Business Wire
ContractPodAi Moves to Microsoft Azure OpenAI in Foundry Models to Accelerate Next Wave of AI Innovation in Legal, Compliance, Procurement, and Regulatory Operations
LONDON--(BUSINESS WIRE)-- ContractPodAi, a leader in legal AI solutions and contract lifecycle management, today announced that it is working with Microsoft to accelerate enterprise adoption of intelligent legal automation. Under the agreement, which builds on a longstanding collaboration between the two organisations, ContractPodAi will combine its domain-specific legal agentic AI platform, Leah, with Microsoft's advanced AI technologies. ContractPodAi will build new agentic AI solutions for legal, procurement, regulatory and compliance use cases, powered by Microsoft's agentic platform, including Azure OpenAI in Foundry Models. ContractPodAi will build new agentic AI solutions for legal, procurement, regulatory and compliance use cases, powered by Microsoft's agentic platform, including Azure OpenAI in Foundry Models. These new tools will transform how legal work gets done by deploying next-generation intelligent AI agents that augment legal teams, automate complex workflows, and redefine efficiency and compliance in legal operations. As part of the agreement, ContractPodAi will be able to scale its offering globally through the Azure Marketplace and unlock opportunities across the Microsoft partner ecosystem. 'We believe in Microsoft's vision for AI and enterprise transformation,' said Sarvarth Misra, CEO and co-founder of ContractPodAi. 'By combining the scale, resilience and security of Microsoft's cloud platform with our legal expertise, we can build intelligent agents that solve complex challenges and raise the bar for what AI can deliver across legal, compliance, and procurement, globally. Our collaboration with Microsoft enables us to scale Leah's impact and reach new levels of innovation in legal AI.' 'ContractPodAi represents a new generation of AI-first innovators who are transforming key industries around the world,' added Darren Hardman, CEO, Microsoft UK. 'By combining Leah with Microsoft's advanced AI technologies, ContractPodAi can drive rapid innovation across the legal agentic AI space, and we look forward to seeing the impact Leah will deliver to organisations around the world.' About ContractPodAi ContractPodAi, a recognized leader in Contract Lifecycle Management and a pioneer in legal GenAI with Leah Legal, is transforming how lawyers author, analyze, and manage documents on an unprecedented scale. ContractPodAi delivers secure, enterprise-ready innovation to accelerate growth and ensure measurable ROI. Going beyond mere task automation, Leah redefines legal processes, empowering strategic thinking and offering real-time analysis. The company has been recognized as a CLM Visionary by Gartner the last four consecutive years and named a Leader in the 2024 IDC MarketScape for Corporate Legal CLM Software. This is more than legal tech; it's Legal Reimagined™. Headquartered in London, ContractPodAi® empowers teams across the world – in New York, Glasgow, San Francisco, Toronto, Sydney, Mumbai, Pune, and more. Follow ContractPodAi on X and LinkedIn to stay in the loop on the latest news.
Business Wire
11-06-2025
- Business Wire
Humata Health Now Available in Microsoft Azure Marketplace
WINTER PARK, Fla.--(BUSINESS WIRE)-- Humata Health, a leader in delivering AI-powered touchless prior authorizations, today announced the availability of its platform in Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. Healthcare payers and providers that want to automate prior authorization can now take advantage of the productive and trusted Azure cloud platform, with streamlined deployment and management. Humata helps patients and members get the care they deserve by transforming prior authorization from end-to-end with artificial intelligence (AI) and automation. For providers, this includes every step from determining if authorization is required for a specific procedure under a patient's specific health plan, through submission, status checks along the way, and post-approval monitoring for any changes that may invalidate a decision. For health plans, receiving higher quality submissions that include the exact information they need in order to provide approval, while automating the review of submissions, increases the speed and volume of approval. 'Humata Health exists for one reason – to make prior authorization easy and seamless for providers, payers and the patients they serve. Becoming a Microsoft partner and making our platform available on the Azure Marketplace is one more way we're fulfilling that mission,' said Humata Health founder and CEO Jeremy Friese, MD. 'With easy access to our technology through the Azure Marketplace, and Azure's robust infrastructure to support our powerful AI and automation technology, the path to frictionless prior authorization for our joint customers is easier than ever before.' Through the Azure Marketplace, Humata can be easily deployed and managed. This includes simple billing options that allow for the Humata platform to be purchased through an organization's Azure invoice. 'Microsoft welcomes Humata Health to Azure Marketplace, where global customers can find, try, and buy from among thousands of partner solutions,' said Jake Zborowski, General Manager, Microsoft Azure Platform at Microsoft Corp. 'Azure Marketplace and trusted partners like Humata Health help customers do more with less by increasing efficiency, buying confidently, and spending smarter.' The Azure Marketplace is an online market for buying and selling cloud solutions certified to run on Azure. The Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use. About Humata Health Humata Health is the leader in delivering AI-powered touchless prior authorizations. With the industry's largest ecosystem of integrations and proprietary technology that gathers the right clinical information required for fast approval, the Humata platform is the only truly end-to-end prior authorization solution for all services and procedures. Humata Health is a physician-led company backed by a syndicate of strategic healthcare investors including Blue Venture Fund, LRVHealth, Optum Ventures, .406 Ventures, and Highmark Ventures. For more information, visit
Yahoo
11-06-2025
- Yahoo
InSilicoTrials Joins Microsoft for Startups Pegasus Program to Accelerate Digital Transformation in Healthcare
WILMINGTON, Del., June 11, 2025--(BUSINESS WIRE)--InSilicoTrials, a health tech company developing simulation-based solutions for drug development, today announced its acceptance into the Microsoft for Startups Pegasus Program, an, invitation-only initiative within Microsoft for Startups, designed to accelerate the growth of high-potential startups. This milestone marks a significant step in InSilicoTrials' mission to modernize healthcare R&D through AI and in silico simulation technologies. The Microsoft for Startups Pegasus Program connects growth-stage startups with Microsoft's global sales channels and enterprise customer network. The program is designed for startups with demonstrated product-market fit and the ability to scale in sectors such as AI, healthcare, cybersecurity, and retail. As part of the Microsoft for Startups Pegasus Program, InSilicoTrials will use Microsoft Azure's cloud infrastructure and AI capabilities to further develop its digital simulation platform. This platform supports pharmaceutical and biotech companies, as well as researchers, in accelerating R&D, optimizing clinical trial designs, and reducing dependence on traditional clinical studies. InSilicoTrials' technology includes digital twin and virtual patient models, AI-based simulations, and privacy-preserving synthetic patient populations—tools designed to improve the efficiency and effectiveness of drug development. "InSilicoTrials is focused on expanding access to simulation and AI tools that help life sciences organizations de-risk faster development of safer, more effective treatments," said Luca Emili, CEO at InSilicoTrials. "Joining the Microsoft for Startups Pegasus Program allows us to scale our reach, enhance our integration with Microsoft Azure, and bring the benefits of in silico trials to more customers worldwide." Participation in the Microsoft for Startups Pegasus Program will also enable InSilicoTrials to offer its solutions via the Azure Marketplace, making it easier for enterprise customers to access its cloud-based platform. The company will also engage in co-sell opportunities and joint go-to-market efforts alongside Microsoft's technical and sales teams. "We are pleased to welcome InSilicoTrials into the Microsoft for Startups Pegasus Program. We look forward to supporting their efforts to bring advanced digital simulation and AI technologies to life sciences organizations that are transforming healthcare, accelerating innovation and accelerating drug development," commented Sally Ann Frank, Global Lead for Health & Life Sciences at Microsoft for Startups. For more information about InSilicoTrials and its digital healthcare solutions, visit About InSilicoTrials InSilicoTrials is a digital health startup founded by experts in life sciences, cybersecurity, and digital innovation. Its cloud-based platform leverages AI and simulation to predict drug safety and efficacy, accelerate R&D, and streamline clinical trial processes for pharmaceutical, biotech, and research organizations. With a global network of more than 70 scientific partners and hundreds of integrated models, InSilicoTrials is helping organizations modernize and improve drug development workflows. View source version on Contacts email address: phone number: +1 (571) 478-0693 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
